Maria Gabriela Morales France

Dr. Maria Gabriela Morales France

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2014 in Skeletal Muscle
Verified
Journal Article
Open access
PDF file
PPPatrizia Pessina
Patrizia Pessina
DCDaniel Cabrera
Daniel Cabrera
MFMaria Gabriela Morales France
Maria Gabriela Morales France
CRCecilia A Riquelme
Cecilia A Riquelme
JGJaime Gutiérrez
Jaime Gutiérrez
PMPura Muñoz-Cánoves
Pura Muñoz-Cánoves
Fibrosis, an excessive collagen accumulation, results in scar formation, impairing function of vital organs and tissues. Fibrosis is a hallmark of muscular dystrophies, including the lethal Duchenne muscular dystrophy (DMD), which remains incurable. Substitution of muscle by fibrotic tissue also complicates gene/cell therapies for DMD. Yet, no optimal models to study muscle fibrosis are available. In the widely used mdx mouse model for DMD, extensive fibrosis develops in the diaphragm only at advanced adulthood, and at about two years of age in the ‘easy-to-access’ limb muscles, thus precluding fibrosis research and the testing of novel therapies.

21 March 2014 in Skeletal Muscle
Verified
Journal Article
Open access
PDF file
DCDaniel Cabrera
Daniel Cabrera
JGJaime Gutiérrez
Jaime Gutiérrez
CCClaudio Cabello-Verrugio
Claudio Cabello-Verrugio
MFMaria Gabriela Morales France
Maria Gabriela Morales France
SMSergio Mezzano
Sergio Mezzano
EBEnrique Brandan
Enrique Brandan
Duchenne muscular dystrophy (DMD) is characterized by the absence of the cytoskeletal protein dystrophin, muscle wasting, increased transforming growth factor type beta (TGF-β) signaling, and fibrosis. At the present time, the only clinically validated treatments for DMD are glucocorticoids. These drugs prolong muscle strength and ambulation of patients for a short term only and have severe adverse effects. Andrographolide, a bicyclic diterpenoid lactone, has traditionally been used for the treatment of colds, fever, laryngitis, and other infections with no or minimal side effects. We determined whether andrographolide treatment of mdx mice, an animal model for DMD, affects muscle damage, physiology, fibrosis, and efficiency of cell therapy.

Verified
Journal Article
Open access
PDF file
ZLZhongyang Lu
Zhongyang Lu
SLShufeng Liu
Shufeng Liu
MFMaria Gabriela Morales France
Maria Gabriela Morales France
AWAndy Whitlock
Andy Whitlock
RRRam Ramkumar
Ram Ramkumar
HRHema Ramkumar
Hema Ramkumar
Dry age-related macular degeneration (AMD) is a leading cause of vision loss in individuals over 50, yet no approved therapies exist for early or intermediate stages of the disease. Oxidative stress is a central driver of retinal degeneration in AMD, and sodium iodate (NaIO3)-induced injury serves as a well-characterized model of oxidative damage to the retinal pigment epithelium (RPE) and photoreceptors. BMI1, a poly-comb group protein involved in DNA repair, mitochondrial function, and cellular renewal, has emerged as a promising therapeutic target for retinal neuroprotection. We evaluated the efficacy of AAV-mediated BMI1 gene delivery in murine models using two administration routes: subretinal (SR) and suprachoroidal (SC). AAV5.BMI1 (1 × 109 vg/eye) was delivered SR in Balb/c mice and evaluated at 4 and 15 weeks post-injection. AAV8.BMI1 (5 × 109 or 1 × 1010 vg/eye) was administered SC in C57BL/6 mice and assessed at 4 weeks. Control groups received BSS or AAV8.stuffer. Following NaIO3 exposure, retinal structure and function were analyzed by optical coherence tomography (OCT), electroretinography (ERG), histology, and molecular assays. SC delivery of AAV8.BMI1 achieved the highest levels of retinal BMI1 expression with no evidence of local or systemic toxicity. Treated eyes showed dose-dependent preservation of outer nuclear layer (ONL) thickness and significantly improved ERG responses indicating structural and functional protection. These findings support SC AAV.BMI1 gene therapy as a promising, minimally invasive, and translatable approach for early intervention in intermediate AMD.

21 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ZLZhongyang Lu
Zhongyang Lu
SLShufeng Liu
Shufeng Liu
MFMaria Gabriela Morales France
Maria Gabriela Morales France
AWAndy Whitlock
Andy Whitlock
RRRam Ramkumar
Ram Ramkumar
HRHema Ramkumar
Hema Ramkumar
Dry age-related macular degeneration (AMD) is a leading cause of blindness in people over 50 with limited therapeutic options. The sodium iodate (NaIO3)-induced retinal degeneration model mimics oxidative stress-induced cell death in dry AMD. BMI1, a polycomb ring finger protein involved in DNA repair and cell renewal, is a potential therapeutic target for oxidative retinal injury. We evaluated the efficacy of AAV-mediated BMI1 gene delivery in Balb/c and C57BL/6 mice using two routes: subretinal (SR) and suprachoroidal (SC). AAV5.BMI1 (1×10⁹ vg/eye) was delivered SR in Balb/c mice, and efficacy was assessed after 4 and 15 weeks. AAV8.BMI1 (5×10⁹ or 1×10¹⁰ vg/eye) was administered SC in C57BL/6 mice, with evaluation after 4 weeks. Control groups received BSS or AAV8.stuffer. Following NaIO₃ administration, retinal function and structure were analyzed by optical coherence tomography (OCT), electroretinography (ERG), histology, and tissue assays. SC delivery of AAV8.BMI1 achieved the highest transduction and BMI1 expression without adverse effects, leading to dose-dependent ONL preservation and improved ERG responses. These findings suggest that SC AAV-mediated BMI1 gene delivery effectively enhances retinal health and function and prevents retinal degeneration, supporting its use as a promising therapeutic approach for intermediate AMD to prevent advanced disease.